BioCardia(BCDA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BCDA BioCardia

Not Yet Opened 12-20 16:00:00 EST

1.97

+0.13

+7.07%

盘后1.97

+0.000.00%

16:36 EST

High2.06	Low1.88	Vol51.54K
Open1.93	D1 Closing1.84	Amplitude9.97%
Mkt Cap9.03M	Tradable Cap7.32M	Total Shares4.58M
T/O100.90K	T/O Rate1.39%	Tradable Shares3.71M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"BCDA","market":"US","secType":"STK","nameCN":"BioCardia","latestPrice":1.97,"timestamp":1734728400000,"preClose":1.84,"halted":0,"volume":51538,"hourTrading":{"tag":"盘后","latestPrice":1.97,"preClose":1.97,"latestTime":"16:36 EST","volume":122,"amount":232.22,"timestamp":1734730585247},"delay":0,"floatShares":3714800,"shares":4584285,"eps":-3.915047,"marketStatus":"Not Yet Opened","change":0.13,"latestTime":"12-20 16:00:00 EST","open":1.93,"high":2.0634,"low":1.88,"amount":100900.416098,"amplitude":0.099674,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-3.915047,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1734944400000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":1.84,"preHourTrading":{"tag":"盘前","latestPrice":1.85,"preClose":1.84,"latestTime":"09:03 EST","volume":1,"amount":1.85,"timestamp":1734703401865},"postHourTrading":{"tag":"盘后","latestPrice":1.97,"preClose":1.97,"latestTime":"16:36 EST","volume":122,"amount":232.22,"timestamp":1734730585247},"volumeRatio":1.2018955003498852,"impliedVol":0.8044,"impliedVolPercentile":0.4821},"requestUrl":"/m/hq/s/BCDA/wiki","defaultTab":"wiki","newsList":[{"id":"2492097045","title":"BioCardia Price Target Maintained With a $25.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2492097045","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492097045?lang=en_us&edition=fundamental","pubTime":"2024-12-18 17:49","pubTimestamp":1734515340,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BCDA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 18, 2024 04:49 ET (09:49 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDA"],"gpt_icon":0},{"id":"2492998518","title":"Positive Outlook on BioCardia: Strategic Growth and Regulatory Advancements Drive Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2492998518","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492998518?lang=en_us&edition=fundamental","pubTime":"2024-12-18 01:05","pubTimestamp":1734455114,"startTime":"0","endTime":"0","summary":"In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on BioCardia (BCDA – Research Report), with a price targe...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/positive-outlook-on-biocardia-strategic-growth-and-regulatory-advancements-drive-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/positive-outlook-on-biocardia-strategic-growth-and-regulatory-advancements-drive-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCDA"],"gpt_icon":0},{"id":"2492561379","title":"BRIEF-Biocardia Announces Commercial Availability Of Morph® Dna™ Steerable Introducer Product Family","url":"https://stock-news.laohu8.com/highlight/detail?id=2492561379","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492561379?lang=en_us&edition=fundamental","pubTime":"2024-12-17 20:18","pubTimestamp":1734437894,"startTime":"0","endTime":"0","summary":"BRIEF-Biocardia Announces Commercial Availability Of Morph® Dna™ Steerable Introducer Product FamilyDec 17 (Reuters) - BioCardia Inc BCDA.O:BIOCARDIA ANNOUNCES COMMERCIAL AVAILABILITY OF MORPH® DNA™ STEERABLE INTRODUCER PRODUCT FAMILYSource text: ID:nGNX5SGhPbFurther company coverage: BCDA.O","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241217:nFWN3NI0C7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDA","BK4139"],"gpt_icon":0},{"id":"2492554869","title":"BioCardia Announces Commercial Availability of Morph® DNA™ Steerable Introducer Product Family","url":"https://stock-news.laohu8.com/highlight/detail?id=2492554869","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492554869?lang=en_us&edition=fundamental","pubTime":"2024-12-17 20:02","pubTimestamp":1734436941,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241217:nFWN3NI0C7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCDA","BK4139"],"gpt_icon":0},{"id":"2492959831","title":"BioCardia Announces Commercial Availability of Morph® DNA™ Steerable Introducer Product Family","url":"https://stock-news.laohu8.com/highlight/detail?id=2492959831","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492959831?lang=en_us&edition=fundamental","pubTime":"2024-12-17 20:00","pubTimestamp":1734436800,"startTime":"0","endTime":"0","summary":"SUNNYVALE, Calif., Dec.  17, 2024  (GLOBE NEWSWIRE) -- BioCardia, Inc.[Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseas","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/17/2998111/0/en/BioCardia-Announces-Commercial-Availability-of-Morph-DNA-Steerable-Introducer-Product-Family.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCDA","DNA","BK4109"],"gpt_icon":0},{"id":"2488219643","title":"BioCardia announces completion of consoltation with Japan’s PMDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2488219643","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488219643?lang=en_us&edition=fundamental","pubTime":"2024-12-04 21:36","pubTimestamp":1733319376,"startTime":"0","endTime":"0","summary":"BioCardia (BCDA) announces the successful completion of a consultation with Japan’s Pharmaceutical and Medical Device Agency, PMDA, on the next ste...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biocardia-announces-completion-of-consoltation-with-japans-pmda?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biocardia-announces-completion-of-consoltation-with-japans-pmda?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BCDA"],"gpt_icon":0},{"id":"2488195493","title":"BioCardia Announces Positive Consultation With Japan Pmda on Cardiamp Cell Therapy for Ischemic Heart Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2488195493","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488195493?lang=en_us&edition=fundamental","pubTime":"2024-12-04 21:30","pubTimestamp":1733319001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241204:nTUA9YGWQP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BCDA"],"gpt_icon":0},{"id":"2488195226","title":"BioCardia Inc - Final Data From Cardiamp Heart Failure Trial Expected Q1 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2488195226","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488195226?lang=en_us&edition=fundamental","pubTime":"2024-12-04 21:30","pubTimestamp":1733319001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241204:nTUA9YGWQP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCDA","BK4139"],"gpt_icon":0},{"id":"2488196285","title":"BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2488196285","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488196285?lang=en_us&edition=fundamental","pubTime":"2024-12-04 21:30","pubTimestamp":1733319000,"startTime":"0","endTime":"0","summary":"Next PMDA Consultation after Review of CardiAMP HF Trial Data. “This most recent meeting with PMDA had several important outcomes,” said Peter Altman, Ph.D., BioCardia’s President and Chief Executive Officer.” First, PMDA has invited our next consultation after the submission of our final clinical data with two-year follow-up to review the sufficiency of evidence to support claims of safety and efficacy for the BCDA-01 program. Second, PMDA remains open to the results from the CardiAMP Heart Failure Trial and our previous trials being sufficient evidence for registering CardiAMP Cell Therapy System for patients with heart failure in Japan.”Dr. Altman continued, “We are working on data lock from our fully enrolled 125 patient CardiAMP Heart Failure Trial and anticipate final data will be available in the first quarter of 2025.”","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/BwoRPiuVsyL9bn0HQQmQTQ--~B/aD0zMDA7dz0xMzMzO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/64948509b7f9139e7048f9073e47bfbf","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/BwoRPiuVsyL9bn0HQQmQTQ--~B/aD0zMDA7dz0xMzMzO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/64948509b7f9139e7048f9073e47bfbf"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biocardia-announces-positive-consultation-japan-133000526.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2637428348.USD","CMS","LU2346227817.USD","BCDAW","BK4588","LU1894683264.USD","LU1894683348.USD","BK4208","BCDA","BK4139","BK4585"],"gpt_icon":0},{"id":"2484620914","title":"Eleven option delistings on November 18th","url":"https://stock-news.laohu8.com/highlight/detail?id=2484620914","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484620914?lang=en_us&edition=fundamental","pubTime":"2024-11-18 21:30","pubTimestamp":1731936610,"startTime":"0","endTime":"0","summary":"Option delistings effective November 18th include BioCardia (BCDA), DBV Technologies (DBVT), ACN 650 026 314 Ltd (DCFCQ), DouYu International (DOYU...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/eleven-option-delistings-on-november-18th?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/eleven-option-delistings-on-november-18th?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4096","DCFCQ","DBVT","BK4509","BK4513","BK4085","DOYU","BCDA"],"gpt_icon":0},{"id":"2483519814","title":"BioCardia Third Quarter 2024 Earnings: US$0.61 loss per share (vs US$1.79 loss in 3Q 2023)","url":"https://stock-news.laohu8.com/highlight/detail?id=2483519814","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483519814?lang=en_us&edition=fundamental","pubTime":"2024-11-16 21:04","pubTimestamp":1731762285,"startTime":"0","endTime":"0","summary":"NasdaqCM:BCDA Earnings and Revenue History November 16th 2024. All figures shown in the chart above are for the trailing 12 month  period. Looking ahead, revenue is forecast to grow 94% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in the US.The company's shares are down 18% from a week ago.We should say that we've discovered 7 warning signs for BioCardia (6 are a bit unpleasant!) that you should be aware of before investing here.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biocardia-third-quarter-2024-earnings-130445792.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BCDAW","BCDA"],"gpt_icon":0},{"id":"2483573338","title":"BioCardia Price Target Maintained With a $25.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2483573338","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483573338?lang=en_us&edition=fundamental","pubTime":"2024-11-15 02:33","pubTimestamp":1731609180,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BCDA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 14, 2024 13:33 ET (18:33 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDA"],"gpt_icon":0},{"id":"2483087837","title":"BioCardia’s Strong Q3 Performance and Strategic Trials Drive Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2483087837","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483087837?lang=en_us&edition=fundamental","pubTime":"2024-11-14 19:16","pubTimestamp":1731582995,"startTime":"0","endTime":"0","summary":"BioCardia (BCDA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H.C....","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/biocardias-strong-q3-performance-and-strategic-trials-drive-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/biocardias-strong-q3-performance-and-strategic-trials-drive-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCDA"],"gpt_icon":0},{"id":"2483843613","title":"BioCardia Inc (BCDA) Q3 2024 Earnings Call Highlights: Breakthroughs and Challenges in Cardiac ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2483843613","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483843613?lang=en_us&edition=fundamental","pubTime":"2024-11-14 15:13","pubTimestamp":1731568429,"startTime":"0","endTime":"0","summary":"For the complete transcript of the earnings call, please refer to the full earnings call transcript.BioCardia Inc  has received FDA breakthrough designation for its lead autologous cardiac cell therapy for heart failure, which is also reimbursed by Medicare and Medicaid.The company is conducting two active clinical trials for its cardiac cell therapy, with promising interim results showing improved survival and reduced major adverse cardiac events.The company successfully closed a $7.2 million public offering, ensuring compliance with Nasdaq's listing requirements and extending its financial runway.Research and development expenses have decreased significantly, reflecting efficient management and completion of enrollment in the cardiac heart failure one trial.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/HywZe.sRwdFFg1.Cdt56qA--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/60923920049f23264f07b5e44a14cc70","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/HywZe.sRwdFFg1.Cdt56qA--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/60923920049f23264f07b5e44a14cc70"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biocardia-inc-bcda-q3-2024-071349073.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BCDA","BCDAW"],"gpt_icon":1},{"id":"2483892642","title":"BioCardia Inc reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2483892642","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483892642?lang=en_us&edition=fundamental","pubTime":"2024-11-14 12:02","pubTimestamp":1731556975,"startTime":"0","endTime":"0","summary":"* BioCardia Inc    reported a quarterly adjusted loss of 61 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-1.80.  The lo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDA"],"gpt_icon":0},{"id":"2483863281","title":"BioCardia Q3 2024 GAAP EPS $(0.61) Beats $(1.19) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2483863281","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483863281?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:33","pubTimestamp":1731533617,"startTime":"0","endTime":"0","summary":"BioCardia (NASDAQ:BCDA) reported quarterly losses of $(0.61) per share which beat the analyst consensus estimate of $(1.19) by 48.74 percent. This is a 65.92 percent increase over losses of $(1.79) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41955923/biocardia-q3-2024-gaap-eps-0-61-beats-1-19-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"BioCardia Q3 2024 GAAP EPS $(0.61) Beats $(1.19) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDA"],"gpt_icon":0},{"id":"2483633448","title":"BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2483633448","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483633448?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:05","pubTimestamp":1731531900,"startTime":"0","endTime":"0","summary":"SUNNYVALE, Calif., Nov. 13, 2024  -- BioCardia, Inc.[Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the third quarter of 2024 and filed its quarterly report on Form 10-Q for the three and nine months ended September 30, 2024 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following management’s formal remarks, there will be a question-and-answer session.CardiAMP autologous cell therapy in ischemic heart failure of reduced ejection fraction . The FDA approved the 510 of our steerable introducer sheath product family for cardiac, aorto-ostial, and peripheral clinical indications in August 2024.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/BwoRPiuVsyL9bn0HQQmQTQ--~B/aD0zMDA7dz0xMzMzO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/64948509b7f9139e7048f9073e47bfbf","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/BwoRPiuVsyL9bn0HQQmQTQ--~B/aD0zMDA7dz0xMzMzO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/64948509b7f9139e7048f9073e47bfbf"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biocardia-reports-third-quarter-2024-210500725.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BCDA","BK4139","BCDAW"],"gpt_icon":0},{"id":"2482971491","title":"BioCardia Inc  expected to post a loss of $1.19 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2482971491","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482971491?lang=en_us&edition=fundamental","pubTime":"2024-11-12 11:47","pubTimestamp":1731383247,"startTime":"0","endTime":"0","summary":"BioCardia Inc  expected to post a loss of $1.19 a share - Earnings Preview BioCardia Inc BCDA.OQ BCDA.O is expected to show a fall in quarterly revenue when it reports  results on November 13 for the ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241112:nL8N3MJ07D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDA"],"gpt_icon":0},{"id":"2481703326","title":"BioCardia to Host Q3 2024 Corporate Update and Financial Results Conference Call on November 13, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2481703326","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481703326?lang=en_us&edition=fundamental","pubTime":"2024-11-06 20:00","pubTimestamp":1730894400,"startTime":"0","endTime":"0","summary":"SUNNYVALE, Calif., Nov. 06, 2024  -- BioCardia, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three and nine months ended September 30, 2024 by conference call on Wednesday, November 13, 2024 at 4:30 PM ET. Following management’s formal remarks, there will be a question-and-answer session.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/BwoRPiuVsyL9bn0HQQmQTQ--~B/aD0zMDA7dz0xMzMzO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/64948509b7f9139e7048f9073e47bfbf","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/BwoRPiuVsyL9bn0HQQmQTQ--~B/aD0zMDA7dz0xMzMzO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/64948509b7f9139e7048f9073e47bfbf"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biocardia-host-q3-2024-corporate-120000027.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HST","BCDAW","BK4139","BCDA","BK4588","BK4585","BK4218","BK4181"],"gpt_icon":0},{"id":"2480809165","title":"BioCardia Inc    expected to post a loss of $1.19 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2480809165","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480809165?lang=en_us&edition=fundamental","pubTime":"2024-11-04 23:42","pubTimestamp":1730734941,"startTime":"0","endTime":"0","summary":"* BioCardia Inc     is expected to show a fall in quarterly revenue when it reports  results on November 6 (estimated) for the period ending September 30 2024   * The Sunnyvale California-based  compa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"BioCardia Inc    expected to post a loss of $1.19 a share - Earnings Preview","news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biocardia.com","stockEarnings":[{"period":"1week","weight":-0.0529},{"period":"1month","weight":-0.0101},{"period":"3month","weight":-0.2244},{"period":"6month","weight":-0.3433},{"period":"1year","weight":-0.7979},{"period":"ytd","weight":-0.8023}],"compareEarnings":[{"period":"1week","weight":-0.0216},{"period":"1month","weight":0.0011},{"period":"3month","weight":0.0403},{"period":"6month","weight":0.0857},{"period":"1year","weight":0.2506},{"period":"ytd","weight":0.2437}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.06938},{"month":2,"riseRate":0.5,"avgChangeRate":-0.000116},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.063445},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.020094},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.051537},{"month":6,"riseRate":0.285714,"avgChangeRate":-0.041157},{"month":7,"riseRate":0.428571,"avgChangeRate":-0.032675},{"month":8,"riseRate":0.285714,"avgChangeRate":-0.106569},{"month":9,"riseRate":0.428571,"avgChangeRate":0.059679},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.068561},{"month":11,"riseRate":0.428571,"avgChangeRate":0.043567},{"month":12,"riseRate":0.428571,"avgChangeRate":-0.007381}],"exchange":"NASDAQ","name":"BioCardia","nameEN":"BioCardia"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BioCardia(BCDA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BioCardia(BCDA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BioCardia,BCDA,BioCardia股票,BioCardia股票老虎,BioCardia股票老虎国际,BioCardia行情,BioCardia股票行情,BioCardia股价,BioCardia股市,BioCardia股票价格,BioCardia股票交易,BioCardia股票购买,BioCardia股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BioCardia(BCDA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BioCardia(BCDA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}